Head to Head Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) and Rosetta Genomics (OTCMKTS:ROSGQ)
Head to Head Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) and Rosetta Genomics (OTCMKTS:ROSGQ)
Rosetta Genomics (OTCMKTS:ROSGQ – Get Rating) and Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability and institutional ownership.
罗塞塔基因(场外交易代码:ROSGQ-GET评级)和Mirum制药(纳斯达克:MIRM-GET评级)都是医药公司,但哪只股票更好?我们将根据这两家公司的盈利实力、分析师建议、股息、估值、风险、盈利能力和机构持股情况对它们进行比较。
Earnings and Valuation
收益和估值
This table compares Rosetta Genomics and Mirum Pharmaceuticals' top-line revenue, earnings per share and valuation.
该表格比较了罗塞塔基因公司和Mirum制药公司的营收、每股收益和估值。
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
Rosetta Genomics | N/A | N/A | N/A | N/A | N/A |
Mirum Pharmaceuticals | $19.14 million | 34.42 | -$83.99 million | ($1.12) | -15.96 |
总收入 | 价格/销售额比 | 净收入 | 每股收益 | 市盈率 | |
罗塞塔基因组学 | 不适用 | 不适用 | 不适用 | 不适用 | 不适用 |
Mirum制药公司 | 1,914万美元 | 34.42 | -8,399万元 | ($1.12) | -15.96 |
Rosetta Genomics has higher earnings, but lower revenue than Mirum Pharmaceuticals.
罗塞塔基因公司的收益高于Mirum制药公司,但营收低于Mirum制药公司。
Institutional and Insider Ownership
机构和内部人持股
Analyst Ratings
分析师评级
This is a breakdown of recent ratings and recommmendations for Rosetta Genomics and Mirum Pharmaceuticals, as provided by MarketBeat.com.
这是由MarketBeat.com提供的罗塞塔基因组公司和Mirum制药公司最近的评级和推荐细目。
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Rosetta Genomics | 0 | 0 | 0 | 0 | N/A |
Mirum Pharmaceuticals | 0 | 0 | 3 | 1 | 3.25 |
销售评级 | 保持评级 | 购买评级 | 强劲的买入评级 | 评级分数 | |
罗塞塔基因组学 | 0 | 0 | 0 | 0 | 不适用 |
Mirum制药公司 | 0 | 0 | 3 | 1 | 3.25 |
Mirum Pharmaceuticals has a consensus price target of $54.20, indicating a potential upside of 203.30%.
Mirum制药的共识目标价为54.2美元,表明潜在涨幅为203.30。
Risk and Volatility
风险和波动性
Rosetta Genomics has a beta of -0.48, suggesting that its share price is 148% less volatile than the S&P 500. Comparatively, Mirum Pharmaceuticals has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
罗塞塔基因公司的贝塔指数为-0.48,这表明其股价的波动性比标准普尔500指数低148%。相比之下,Mirum PharmPharmticals的贝塔系数为1.34,这表明其股价的波动性比标准普尔500指数高34%。
Profitability
盈利能力
This table compares Rosetta Genomics and Mirum Pharmaceuticals' net margins, return on equity and return on assets.
此表比较了罗塞塔基因公司和Mirum制药公司的净利润率、股本回报率和资产回报率。
Net Margins | Return on Equity | Return on Assets | |
Rosetta Genomics | N/A | N/A | N/A |
Mirum Pharmaceuticals | -79.72% | -99.78% | -41.16% |
净利润率 | 股本回报率 | 资产回报率 | |
罗塞塔基因组学 | 不适用 | 不适用 | 不适用 |
Mirum制药公司 | -79.72% | -99.78% | -41.16% |
Summary
摘要
Mirum Pharmaceuticals beats Rosetta Genomics on 6 of the 9 factors compared between the two stocks.
Mirum PharmPharmticals在两只股票比较的9个因素中有6个击败了罗塞塔基因公司。
About Rosetta Genomics
关于罗塞塔基因组学
(Get Rating)
(获取评级)
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests. It also provides UroVysion, a urine-based Fluorescence In Situ Hybridization (FISH) assay that is intended for use in conjunction with and not in lieu of current standard diagnostic procedures, as an aid for initial diagnosis of bladder carcinoma in patients with hematuria and subsequent monitoring for tumor recurrence in patients previously diagnosed with bladder cancer; and ERG/PTEN, which are FISH-based prognostic tests in prostate cancer. In addition, the company offers ALK/ROS1 that are FISH-based predictive tests indicated for patients who are diagnosed with late stage lung cancer; and PCR gene mutation analysis for bladder, lung, colon, and melanoma patients. The company provides its diagnostic solutions for oncologists, urologists, endocrinologists, cytopathologists, and other specialists to facilitate them in serving their patients. It has a license agreement with Max Planck Innovation GmbH for the rights to its proprietary microRNAs for diagnostics and research purposes. The company also has a collaboration agreement with Meir Medical Center to develop a microRNA classifier relating to patients with non-small cell lung cancer considered for treatment with immuno oncology drugs. Rosetta Genomics Ltd. was founded in 2000 and is headquartered in Rehovot, Israel.
罗塞塔基因有限公司是一家全球性的基因组诊断公司。该公司基于microRNA技术的诊断测试包括用于确定转移性癌症原发部位的RosettaGX癌症起源;用于病理样本的肾脏肿瘤分类测试;用于诊断不确定的甲状腺细针抽吸样本的RosettaGX Display;以及半肺诊断测试。它还提供了UroVysion,这是一种基于尿液的荧光原位杂交(FISH)检测,旨在与当前的标准诊断程序一起使用,而不是取代现有的标准诊断程序,作为对有血尿的患者的膀胱癌的初步诊断以及随后对先前诊断为膀胱癌的患者的肿瘤复发的监测;以及ERG/PTEN,这是基于FISH的前列腺癌预后检测。此外,该公司还提供ALK/ROS1,这是一种基于FISH的预测测试,适用于被诊断为晚期肺癌的患者;以及用于膀胱癌、肺癌、结肠癌和黑色素瘤患者的PCR基因突变分析。该公司为肿瘤学家、泌尿科医生、内分泌学家、细胞病理学家和其他专家提供诊断解决方案,以方便他们为患者服务。它与Max Planck Innovation GmbH签署了一项许可协议,获得用于诊断和研究目的的专有microRNA的权利。该公司还与梅尔医疗中心达成了一项合作协议,开发一种与考虑使用免疫肿瘤药物治疗的非小细胞肺癌患者有关的MicroRNA分类器。罗塞塔基因有限公司成立于2000年,总部设在以色列雷霍沃特。
About Mirum Pharmaceuticals
关于Mirum制药公司
(Get Rating)
(获取评级)
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
Mirum制药公司是一家生物制药公司,专注于开发和商业化治疗令人衰弱的罕见和孤儿疾病的新疗法。该公司的主要候选产品是LIVMARLI,这是一种研究用口服药物,用于治疗进行性家族性肝内胆汁淤积症,以及治疗Alagille综合征和胆道闭锁疾病。它还开发了治疗妊娠期肝内胆汁淤积症和原发性硬化性胆管炎的伏利昔巴药物。Mirum制药公司成立于2018年,总部位于加利福尼亚州福斯特城。
Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《罗塞塔基因组学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Rosetta Genology和相关公司的最新新闻和分析师评级的每日简要摘要。